SCHEMBL372276

SCHEMBL372276

Nc1ccccc1C(CC(=O)O)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.57
TSHR P16473 2/20 0.57
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 3/20 0.46
HSD17B10 Q99714 2/20 0.46
POLB P06746 2/20 0.46
USP2 O75604 1/20 0.46
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
CPA1 P15085 2/20 0.42
CPB2 Q96IY4 2/20 0.42
GABBR2 O75899 1/20 0.42
GABBR1 Q9UBS5 1/20 0.42
CPB1 P15086 1/20 0.42
CPA3 P15088 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
GAA P10253 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
KYNU Q16719 2/20 0.39
CYP2C19 P33261 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL21405660 0.81 LMNA (0.40) CYP1A2TSHRALDH1A1HSD17B10POLB
SCHEMBL31357901 0.81 LMNA (0.40) CYP1A2TSHRALDH1A1HSD17B10POLB
SCHEMBL372487 0.81 LMNA (0.40) CYP1A2TSHRALDH1A1HSD17B10POLB
SCHEMBL19951679 0.79 PPARG (0.39) CYP1A2TSHRKDM4EALDH1A1HSD17B10
SCHEMBL1162115 0.79 PPARG (0.39) CYP1A2TSHRKDM4EALDH1A1HSD17B10
SCHEMBL10435608 0.79 CYP2C19 (0.42) CYP1A2TSHRKDM4EMEN1KMT2A
SCHEMBL28306686 0.79 CYP1A2 (0.54) CYP1A2TSHRKDM4EALDH1A1HSD17B10
SCHEMBL10692703 0.78 CYP1A2 (0.57) CYP1A2TSHRKDM4EALDH1A1HSD17B10
SCHEMBL1644947 0.78 FFAR1 (0.47) CYP1A2TSHRKDM4EALDH1A1CPA1
SCHEMBL10523946 0.78 GABBR2 (0.42) CYP1A2TSHRKDM4EPOLBCPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106749373-B Rubber additive and preparation and application thereof 同济大学 2020-06-26 CN disclosed
EP-2409569-B1 Method for administering GLP-1 molecules EMISPHERE TECH INC (US) 2017-08-16 EP disclosed
EP-1478233-B1 METHOD FOR ADMINISTERING GLP-1 MOLECULES EMISPHERE TECH INC (US) 2016-11-09 EP disclosed
EP-1015008-B1 COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECH INC (US) 2015-08-05 EP disclosed
US-20150202296-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2015-07-23 US disclosed
US-8785381-B2 Oral GLP-1 formulations EMISPHERE TECHNOLOGIES, INC. (US) 2014-07-22 US disclosed
US-20140005106-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES EMISPHERE TECHNOLOGIES, INC. (US) 2014-01-02 US disclosed
US-8492330-B2 Formulation comprising GLP-1 EMISPHERE TECHNOLOGIES, INC. (US) 2013-07-23 US disclosed
EP-2409569-A2 Method for administering GLP-1 molecules Emisphere Technologies, Inc. (US) 2012-01-25 EP disclosed
US-20110178006-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES EMISPHERE TECHNOLOGIES, INC. (US) 2011-07-21 US disclosed
US-5879681-A Compounds and compositions for delivering active agents EMISPHERE TECHNOLGIES INC. (US) 1999-03-09 US disclosed
US-5876710-A DRUG DELIVERY; USING A BROMINATED BENZAMIDE COMPOUND EMISPHERE TECHNOLOGIES INC. (US) 1999-03-02 US disclosed
US-5804688-A 6-N-(3,5-DICHLORO-2-HYDROXYBENZOYL)AMINOCAPROIC ACID EMISPHERE TECHNOLOGIES, INC. (US) 1998-09-08 US disclosed
WO-1998034632-A1 COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 1998-08-13 WO disclosed
US-5776888-A 3-(DIMETHOXYBENZOYLAMINOPHENYL) PROPIONIC ACID EMISPHERE TECHNOLOGIES, INC. (US) 1998-07-07 US disclosed
US-5773647-A USING A AROMATIC COMPOUND CONTAINING AMIDE AND CARBOXY GROUPS EMISPHERE TECHNOLOGIES, INC. (US) 1998-06-30 US disclosed
US-5583020-A IONIZATION; DRUG DELIVERY RIBOZYME PHARMACEUTICALS, INC. (US) 1996-12-10 US disclosed
EP-0669926-A1 PERMEABILITY ENHANCERS FOR IONIC THERAPEUTIC POLYMERS RIBOZYME PHARMACEUTICALS, INC. (US) 1995-09-06 EP disclosed
WO-1994012516-A9 PERMEABILITY ENHANCERS FOR IONIC THERAPEUTIC POLYMERS 1994-08-04 WO disclosed
WO-1994012516-A1 PERMEABILITY ENHANCERS FOR IONIC THERAPEUTIC POLYMERS RIBOZYME PHARMACEUTICALS, INC. (US) 1994-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150202296-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 CYP1A2 2415/4885TSHR 125/4885KDM4E 4046/4885
US-20110178006-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 CYP1A2 2415/4885TSHR 125/4885KDM4E 4046/4885
US-20140005106-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 CYP1A2 2415/4885TSHR 125/4885KDM4E 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.